For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Total operating expenses | - | 115,805 | ||
| Total revenues | 4,040 | 1,139 | ||
| Cost of sales | 4,647 | - | ||
| Research and development | 116,641 | 82,102 | ||
| General and administrative | 73,526 | 33,703 | ||
| Total operating costs and expenses | 194,814 | - | ||
| Loss from operations | -190,774 | -114,666 | ||
| Interest income, net | 29,931 | 26,624 | ||
| Other (expense) income, net | -152 | 3 | ||
| Total other income, net | 29,779 | 26,627 | ||
| Net loss and comprehensive loss | -160,995 | -88,039 | ||
| Net loss attributable to common stockholders | -160,995 | -88,039 | ||
| Basic EPS | -2.08 | -1.41 | ||
| Diluted EPS | -2.08 | -1.41 | ||
| Basic Average Shares | 77,303,440 | 62,496,725 | ||
| Diluted Average Shares | 77,303,440 | 62,496,725 | ||
CG Oncology, Inc. (CGON)
CG Oncology, Inc. (CGON)